|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0007226,
umls-concept:C0030705,
umls-concept:C0035647,
umls-concept:C0068707,
umls-concept:C0071097,
umls-concept:C0074554,
umls-concept:C0087111,
umls-concept:C0948265,
umls-concept:C1274040,
umls-concept:C2603343
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-10-22
|
|
pubmed:abstractText |
The aim of the study was to analyze the effect of pioglitazone (PIO) and simvastatin (SIMVA) on adiponectin and visfatin concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications in a prospective randomized clinical trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adiponectin,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypolipidemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Nicotinamide...,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos,
http://linkedlifedata.com/resource/pubmed/chemical/Simvastatin,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones,
http://linkedlifedata.com/resource/pubmed/chemical/adiponectin, human,
http://linkedlifedata.com/resource/pubmed/chemical/hemoglobin A1c protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/pioglitazone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0018-5043
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
764-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17952841-Adiponectin,
pubmed-meshheading:17952841-Aged,
pubmed-meshheading:17952841-Biological Markers,
pubmed-meshheading:17952841-Cardiovascular Diseases,
pubmed-meshheading:17952841-Double-Blind Method,
pubmed-meshheading:17952841-Drug Therapy, Combination,
pubmed-meshheading:17952841-Female,
pubmed-meshheading:17952841-Hemoglobin A, Glycosylated,
pubmed-meshheading:17952841-Humans,
pubmed-meshheading:17952841-Hypolipidemic Agents,
pubmed-meshheading:17952841-Male,
pubmed-meshheading:17952841-Metabolic Syndrome X,
pubmed-meshheading:17952841-Middle Aged,
pubmed-meshheading:17952841-Nicotinamide Phosphoribosyltransferase,
pubmed-meshheading:17952841-Placebos,
pubmed-meshheading:17952841-Risk Factors,
pubmed-meshheading:17952841-Simvastatin,
pubmed-meshheading:17952841-Thiazolidinediones
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study.
|
|
pubmed:affiliation |
1Institute for Clinical Research and Development, Mainz, Germany.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
